Novartis drug combo shows promise in childhood brain cancer

Published by

FRANKFURT (Reuters) – An oral drug combination by Swiss pharmaceuticals company Novartis showed promise in treating a subgroup of patients suffering from a common childhood brain cancer in a trial. In the mid-stage trial, 47% of the patients that were given the two drugs Tafinlar and Mekinist saw their tumours shrink, far above a rate of 11% in a comparative group of participants on standard chemotherapy, the drugmaker said on Monday. The participants, aged 1 to 17 years, were suffering from low-grade gliomas (LGG), the most common childhood brain cancer, which is diagnosed in more than 1,000 …

Read More

Leave a Reply